Home › Compare › HLPMF vs ABBV
HLPMF yields 4.51% · ABBV yields 3.06%● Live data
📍 HLPMF pulled ahead of the other in Year 3
Combined, HLPMF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HLPMF + ABBV for your $10,000?
HELLENiQ ENERGY Holdings S.A., together with its subsidiaries, operates in the energy sector primarily in Greece, South Eastern Europe, and the East Mediterranean. It operates through the Refining, Marketing, Exploration and Production of Hydrocarbons, Petro-chemicals, Gas and Power, and Other segments. The company engages in the refining, supply, and trading of petroleum products; marketing of fuels; production and trading of petrochemicals/chemicals; exploration and production of oil and gas; and generation and trading of power. It is also involved in the production, distribution, and trading of renewable energy sources; provision of financing and other financial services; retail trade of liquid fuels and LPG; operation of tankers; exploration and production of hydrocarbons; trade, distribution, and storage of oil products; and construction and operation of crude oil pipelines. In addition, the company engages in the owning of vessels; production and marketing of lubricants, polypropylene, and solvents; trading of imported plastics and chemicals; production and trade of BOPP films; construction and operation of fuel storage facilities; and provision of treasury, consulting, and engineering services. It operates a network of 1,682 service stations, 15 fuel storage and distribution facilities, 24 aircraft refueling stations in the Greek airports, 2 LPG bottling plants, and 1 lubricant production and packing site in Greece. The company was formerly known as Hellenic Petroleum Holdings Societe Anonyme and changed its name to HELLENiQ ENERGY Holdings S.A. in September 2022. HELLENiQ ENERGY Holdings S.A. was founded in 1998 and is headquartered in Marousi, Greece.
Full HLPMF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.